Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Peter Nolan | M | 75 |
University of Cambridge
| 45 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Khaled Asad Nasr | M | 66 |
University of Cambridge
| 3 years |
| Belita S. Ong | F | - |
University of Cambridge
| 4 years |
| Trevor Thomas | M | - |
University of Cambridge
| 7 years |
| Teck Huat Tan | M | 63 |
University of Cambridge
| 4 years |
| James Edward Smith | M | 71 |
University of Cambridge
| 3 years |
| Yong Nang Tan | M | 62 |
University of Cambridge
| 4 years |
| Woon Kwong Seow | M | 63 |
University of Cambridge
| 4 years |
| Paul Young | M | 68 |
University of Cambridge
| 4 years |
| John Parsons | M | - |
University of Cambridge
| 1 years |
| Richard Morrissey | M | 68 |
University of Cambridge
| 2 years |
| Vijay Perapti | F | - |
University of Cambridge
| 4 years |
| Robert Charles Standing | M | 64 |
University of Cambridge
| 4 years |
| Nobuyori Kodaira | M | 75 |
University of Cambridge
| 1 years |
| Howard Castle-Smith | M | 65 |
University of Cambridge
| 1 years |
| William Graham Cooper | M | 67 |
University of Cambridge
| 1 years |
| Martyn King | M | - |
University of Cambridge
| 4 years |
| Huan Ping Low | M | 68 |
University of Cambridge
| 4 years |
| David Scopes | M | - |
Senexis Ltd.
 Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | 9 years |
| Dong-Gun Kim | M | 77 |
University of Cambridge
| 3 years |
| Steven Troop | M | - |
University of Cambridge
| 4 years |
| Craig Neil Duncan | M | - |
University of Cambridge
| 3 years |
| Joe Liebeschuetz | M | - |
University of Cambridge
| 4 years |
| Philip Hanson | M | 67 |
University of Cambridge
| 4 years |
| Andrew Broomhead | M | 63 |
University of Cambridge
| 4 years |
| Nigel Keith Anthony Standish Vaz | M | 67 |
University of Cambridge
| 4 years |
| Jem Davies | M | - |
University of Cambridge
| 3 years |
| Alison Beckett | F | 62 |
University of Cambridge
| 3 years |
| Wendy Green | F | - |
University of Cambridge
| 4 years |
| Rakesh Sarna | M | - |
University of Cambridge
| 3 years |
| Timothy Clissold | M | 64 |
University of Cambridge
| 4 years |
| Nai Pong Wai | M | 70 |
University of Cambridge
| 4 years |
| Thomas Michael Taylor | M | 68 |
University of Cambridge
| 4 years |
| Dame Anne Glover | M | - |
University of Cambridge
| 3 years |
| Najeeb Samie | M | - |
University of Cambridge
| 3 years |
| Howard Sheppard | M | - |
Senexis Ltd.
Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | - |
| Tony H. J. Quick | M | 68 |
University of Cambridge
| 3 years |
| T. Paul McCubbin | M | - |
Senexis Ltd.
Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | - |
| Steven C. Schroer | M | - |
University of Cambridge
| 3 years |
| Dennis Mulhaupt | M | - |
University of Cambridge
| 3 years |
| Geoffrey G. Davis | M | - |
University of Cambridge
| 3 years |
| Ash Banerjee | M | - |
University of Cambridge
| 4 years |
| Peter Foster | M | 64 |
University of Cambridge
| 4 years |
| Robert Robinson | M | - |
University of Cambridge
| 3 years |
| Joanna Mary Gordon Perry | F | 67 |
University of Cambridge
| 3 years |
| Keith Philip Watkins | M | - |
University of Cambridge
| 3 years |
| Richard Graeme Goodman | M | 66 |
University of Cambridge
| 3 years |
| Simon Caffyn | M | 63 |
University of Cambridge
| 4 years |
| Gareth Beynon | M | - |
University of Cambridge
| 3 years |
| Gordon Cudmore | M | - |
University of Cambridge
| 3 years |
| Nigel Clifford | M | 65 |
University of Cambridge
| 3 years |
| Richard Horlick | M | 65 |
University of Cambridge
| 1 years |
| Beatriz Pessoa de Araujo | F | - |
University of Cambridge
| 4 years |
| Kwok-Kuen Leong | M | 63 |
University of Cambridge
| 4 years |
| Reyaz A. Ahmad | M | - |
University of Cambridge
| 5 years |
| Edward Beale | M | 64 |
University of Cambridge
| 4 years |
| Colin Meadows White | M | 62 |
University of Cambridge
| 4 years |
| James Anthony McNaught-Davis | M | 65 |
University of Cambridge
| 2 years |
| Jonathan Treherne | M | 63 |
Senexis Ltd.
Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | - |
| Yiannis Petrides | M | 66 |
University of Cambridge
| 4 years |
| Jeremy Levin | M | 70 |
University of Cambridge
| 2 years |
| Yoshitaka Kitao | M | 73 |
University of Cambridge
| 4 years |
| Andrew Hopper | M | 71 |
University of Cambridge
| 3 years |
| Bennett Yankowitz | M | 68 |
University of Cambridge
| 3 years |
| Dominic Casserley | M | 67 |
University of Cambridge
| 4 years |
| Michael G. Hack | M | 67 |
University of Cambridge
| 3 years |
| David Checkel | M | - |
University of Cambridge
| 2 years |
| Dario Cossutta | M | 73 |
University of Cambridge
| 1 years |
| Charles Baker | M | 66 |
University of Cambridge
| 4 years |
| Andrew Hewson | M | 65 |
University of Cambridge
| 3 years |
| Jonathan Mark Huntley | M | - |
University of Cambridge
| 4 years |
| Andrew Unitt | M | 66 |
University of Cambridge
| 4 years |
| Adrian Eastwood | M | 63 |
University of Cambridge
| 4 years |
| Brij Mohan Tirath R. Kataria | M | - |
University of Cambridge
| 1 years |
| Anthony Mark Savill | M | - |
University of Cambridge
| 3 years |
| Mike Aspinwall | M | - |
University of Cambridge
| 4 years |
| Bella Ann Almeida | F | 68 |
University of Cambridge
| 3 years |
| Alastair K. Livesey | M | 67 |
University of Cambridge
| 4 years |
| Christopher Abell | M | - |
University of Cambridge
| 3 years |
| Andrew Galazka | M | 69 |
University of Cambridge
| 3 years |
| Mark Francis McAllister | M | 66 |
University of Cambridge
| 1 years |
| Antony D. Buss | M | - |
University of Cambridge
| 3 years |
| John Bailey | M | - |
University of Cambridge
| 1 years |
| Jonathan Charles Kingsman | M | 67 |
University of Cambridge
| 2 years |
| Adam C. Baker | M | - |
University of Cambridge
| 1 years |
| David E. Gill | M | - |
University of Cambridge
| 4 years |
| Peter Jackson | M | 62 |
University of Cambridge
| 4 years |
| Anthony Ian Walker | M | - |
University of Cambridge
| 3 years |
| Paul J. Carter | M | - |
University of Cambridge
| 4 years |
| Shoong Tat Cheng | M | 63 |
University of Cambridge
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 90 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christopher Moyses
- Personal Network
